Last reviewed · How we verify
LY3305677
At a glance
| Generic name | LY3305677 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder (PHASE2)
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (PHASE2)
- A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight (PHASE2)
- A Study of LY3305677 in Participants With Obesity Or Overweight (PHASE1)
- A Study of LY3305677 in Participants With Type 2 Diabetes (PHASE1)
- A Study of Multiple Doses of LY3305677 in Healthy Participants (PHASE1)
- A Study of LY3305677 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3305677 CI brief — competitive landscape report
- LY3305677 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI